Literature DB >> 28520210

Biases in the reporting of hepatocellular carcinoma tumor sizes on the liver transplant waiting list.

Mariya L Samoylova1, Mark J Nigrini2, Jennifer L Dodge3, John P Roberts3.   

Abstract

We investigated the possibility that patients with hepatocellular carcinoma (HCC) listed for liver transplant with tumors just outside stage T2 size criteria may be inaccurately reported as just meeting the tumor size criteria for transplant. The United Network for Organ Sharing/Standard Transplant Analysis and Research database identified 12,958 patients listed for liver transplants with HCC exception points from 2006 to 2013, 9,168 of whom were listed with one tumor. A logistic power peak function was fitted to the single-tumor size histogram, with the fitted values representing unbiased expected values. The difference between the observed and expected tumor counts for 2.0 cm and 5.0 cm was 238 (22%) and 66 (57%), respectively. This suggests that up to 304 (3.0%) patients with tumors outside of transplant criteria had their measurements recorded at the margins of eligibility. A risk-adjusted Poisson model evaluated the ratio of observed to expected HCC recurrence by tumor size. There were 435 HCC recurrences among 6,049 transplants. Only 2.0-cm tumors had observed to expected recurrence differing from 1 (ratio 0.73, 95% confidence interval 0.57-0.94), indicating a 27% lower than expected rate of recurrence.
CONCLUSION: Higher than expected observed tumor counts at the lower transplant criteria margin were corroborated by lower than expected HCC recurrence, suggesting that tumor sizes at the margins of HCC transplant criteria may be subject to inaccurate reporting. (Hepatology 2017;66:1144-1150).
© 2017 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2017        PMID: 28520210      PMCID: PMC5605395          DOI: 10.1002/hep.29269

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  8 in total

1.  Intra- and interobserver variability in CT measurements in oncology.

Authors:  Aoife McErlean; David M Panicek; Emily C Zabor; Chaya S Moskowitz; Richard Bitar; Robert J Motzer; Hedvig Hricak; Michelle S Ginsberg
Journal:  Radiology       Date:  2013-07-03       Impact factor: 11.105

2.  Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes.

Authors:  Geoffrey R Oxnard; Binsheng Zhao; Camelia S Sima; Michelle S Ginsberg; Leonard P James; Robert A Lefkowitz; Pingzhen Guo; Mark G Kris; Lawrence H Schwartz; Gregory J Riely
Journal:  J Clin Oncol       Date:  2011-07-05       Impact factor: 44.544

3.  OPTN/SRTR 2015 Annual Data Report: Liver.

Authors:  W R Kim; J R Lake; J M Smith; M A Skeans; D P Schladt; E B Edwards; A M Harper; J L Wainright; J J Snyder; A K Israni; B L Kasiske
Journal:  Am J Transplant       Date:  2017-01       Impact factor: 8.086

4.  Analysis of interobserver and intraobserver variability in CT tumor measurements.

Authors:  K D Hopper; C J Kasales; M A Van Slyke; T A Schwartz; T R TenHave; J A Jozefiak
Journal:  AJR Am J Roentgenol       Date:  1996-10       Impact factor: 3.959

5.  Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.

Authors:  Alejandro Forner; Ramón Vilana; Carmen Ayuso; Lluís Bianchi; Manel Solé; Juan Ramón Ayuso; Loreto Boix; Margarita Sala; María Varela; Josep M Llovet; Concepció Brú; Jordi Bruix
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

6.  Validating posttransplant hepatocellular carcinoma recurrence data in the United Network for Organ Sharing database.

Authors:  Mariya L Samoylova; Jennifer L Dodge; Eric Vittinghoff; Francis Y Yao; John Paul Roberts
Journal:  Liver Transpl       Date:  2013-10-21       Impact factor: 5.799

7.  Measurements of Hepatic Metastasis on MR Imaging:: Assessment of Interobserver and Intersequence Variability.

Authors:  Ibrahim Karademir; Emily Ward; Yahui Peng; Leon Wise; Christopher Buckle; Rangesh Kunnavakkam; Aytekin Oto
Journal:  Acad Radiol       Date:  2015-11-11       Impact factor: 3.173

8.  APASL and AASLD Consensus Guidelines on Imaging Diagnosis of Hepatocellular Carcinoma: A Review.

Authors:  Cher Heng Tan; Su-Chong Albert Low; Choon Hua Thng
Journal:  Int J Hepatol       Date:  2011-04-19
  8 in total
  6 in total

1.  Risk Factors and Center-Level Variation in Hepatocellular Carcinoma Under-Staging for Liver Transplantation.

Authors:  Nadim Mahmud; Maarouf A Hoteit; David S Goldberg
Journal:  Liver Transpl       Date:  2020-08       Impact factor: 5.799

2.  Down staging of hepatocellular carcinoma-can we push the boundaries?

Authors:  Joydeep Chakraborty; Andreas Giovanni Zori; Roniel Cabrera
Journal:  Hepatobiliary Surg Nutr       Date:  2020-08       Impact factor: 7.293

3.  Alpha-Fetoprotein Decrease from > 1,000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes.

Authors:  Neil Mehta; Jennifer L Dodge; John P Roberts; Ryutaro Hirose; Francis Y Yao
Journal:  Hepatology       Date:  2019-02-10       Impact factor: 17.425

4.  Predictors of low risk for dropout from the liver transplant waiting list for hepatocellular carcinoma in long wait time regions: Implications for organ allocation.

Authors:  Neil Mehta; Jennifer L Dodge; Ryutaro Hirose; John P Roberts; Francis Y Yao
Journal:  Am J Transplant       Date:  2019-04-05       Impact factor: 8.086

5.  National Experience on Down-Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha-Fetoprotein, and Wait Time.

Authors:  Neil Mehta; Jennifer L Dodge; Joshua D Grab; Francis Y Yao
Journal:  Hepatology       Date:  2019-10-15       Impact factor: 17.425

Review 6.  Hepatocellular Carcinoma: Downstaging to Liver Transplantation as Curative Therapy.

Authors:  Leana Frankul; Catherine Frenette
Journal:  J Clin Transl Hepatol       Date:  2021-03-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.